Optic nerve

Science Corporation Acquires Pixium’s PRIMA Retinal Implant, Extending and Diversifying Its Commitment to Vision Restoration Through Brain-Computer Interface Technology

Retrieved on: 
Thursday, April 25, 2024
Research, Medical Devices, Genetics, Clinical Trials, Health Technology, Biotechnology, Health, Optical, Science, Diamond, Blog, Stanford University, AMD, IP, Cell, Corporation, RP, Retinitis pigmentosa, BCI, Paratriathlon, Trigeminal ganglion, Retina, PRIMA, Patient, Acquisition, Optic nerve, Clinical trial, Medical imaging

Science Corporation (“Science”), a leader in brain-computer interface (“BCI”) technology and the developer of the Science Eye , has acquired the IP and related assets for the PRIMA retinal implant , developed by Pixium Vision SA (“Pixium”) of France, a bioelectronics BCI technology company.

Key Points: 
  • Science Corporation (“Science”), a leader in brain-computer interface (“BCI”) technology and the developer of the Science Eye , has acquired the IP and related assets for the PRIMA retinal implant , developed by Pixium Vision SA (“Pixium”) of France, a bioelectronics BCI technology company.
  • Together with the work being done at Science on the Science Eye, we now have two great opportunities to develop BCI technology for the potential restoration of vision in certain patients with severe vision loss.
  • Pixium’s PRIMA system features a miniaturized, wireless, subretinal implant (originally developed at Stanford University) paired with a pocket computer, and glasses.
  • Science CEO Hodak continued: “Science is now developing advanced innovative products using two very different modalities.

Orphan designation: Tranilast Prevention of scarring post glaucoma filtration surgery, 27/07/2010 Positive

Retrieved on: 
Thursday, April 18, 2024
Eurostat, Diagnosis, Civil service commission, Optic nerve, Brain, Pressure, Cell, Disease, Risk, Patient, Committee, Knowledge, Regulation, Cancer, EMA, IRIS, Scar, Eye, Wound healing, European, Allergic conjunctivitis, COMP, Collagen, Skin, European Commission, Safety, Glaucoma, Sclera, Pharmaceutical industry

Orphan designation: Tranilast Prevention of scarring post glaucoma filtration surgery, 27/07/2010 Positive

Key Points: 


Orphan designation: Tranilast Prevention of scarring post glaucoma filtration surgery, 27/07/2010 Positive

Orphan designation: N-((R)-2,3-dihydroxypropoxyl)-3,4-difluro-2-(2-fluoro-4-iodo-phenylamino)-benzamide Treatment of neurofibromatosis type 1, 25/07/2019 Positive

Retrieved on: 
Thursday, April 18, 2024
Eurostat, Diagnosis, Civil service commission, Optic nerve, Brain, Enzyme, Growth, Cell, NF1, Disease, Nervous system, Risk, Groin, Patient, Committee, Knowledge, Neoplasm, Regulation, Cancer, EMA, IRIS, Eye, European, Therapy, COMP, Safety, European Commission, Marketing, Medicine, Pharmaceutical industry

Orphan designation: N-((R)-2,3-dihydroxypropoxyl)-3,4-difluro-2-(2-fluoro-4-iodo-phenylamino)-benzamide Treatment of neurofibromatosis type 1, 25/07/2019 Positive

Key Points: 


Orphan designation: N-((R)-2,3-dihydroxypropoxyl)-3,4-difluro-2-(2-fluoro-4-iodo-phenylamino)-benzamide Treatment of neurofibromatosis type 1, 25/07/2019 Positive

Center For Sight Implants New FDA-Approved iDose®TR Device

Retrieved on: 
Tuesday, March 26, 2024
Surgery, Medical Devices, FDA, Hospitals, Biotechnology, Other Health, Health, General Health, Optical, Optic nerve, Ocular hypertension, Paratriathlon, Patient, Cataract, Eye, Multimedia, Intraocular pressure, Food, Medical device

The iDoseTR implant, manufactured by Glaukos Corporation, is a sustained release ophthalmic implant that is surgically placed in the eye.

Key Points: 
  • The iDoseTR implant, manufactured by Glaukos Corporation, is a sustained release ophthalmic implant that is surgically placed in the eye.
  • The device consistently distributes a travoprost formula to help reduce intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
  • is a member of the US Eye Physician Advisory Board and is a Cataract and Glaucoma Surgeon at Center For Sight.
  • Speaking of the device, he shares, “We found the device and medication formula to work very well in our study patients.

Good News--MS Drugs Taken While Breastfeeding May Not Affect Child Development

Retrieved on: 
Tuesday, March 5, 2024
NMOSD, Social media, Hellwig, Nervous system, Alzheimer's disease, MD, Ofatumumab, Stroke, German, Pregnancy, Life, Risk, Annual general meeting, Multiple sclerosis, DSM-IV codes, AAN, Health, Migraine, Parkinson's disease, Hypoesthesia, Fatigue, Ruhr University Bochum, Mother, Paresthesia, Infant, Concussion, Spinal cord, Breast milk, Epilepsy, Sclerosis, Disease, Child, Rituximab, Natalizumab, Optic nerve, Brain, Demyelinating disease, Research, Immune system, American Academy, Birth control

MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.

Key Points: 
  • MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.
  • For the study, researchers used the German MS and Pregnancy Registry to identify 183 infants born to mothers taking monoclonal antibodies while breastfeeding.
  • The first exposures to the medications through breastfeeding ranged from the day a child was born to the ninth month of life.
  • After comparing infants exposed to the medications to infants not exposed, researchers found no differences in their health or development.

Caregivers Cheer First Patients at New Intermountain Primary Children’s Hospital, Miller Family Campus in Lehi, Utah

Retrieved on: 
Monday, February 12, 2024
Intermountain West, MOGAD, Liver, Child, Central nervous system, Ulcerative colitis, Caregiver, Gymnastics, Intermountain Health, Courage, Friends, Basketball, Hospital, Primary sclerosing cholangitis, Hope, Communication, Bile, Arthralgia, University, Life flight, Nursing, Patient, Myasthenia gravis, Optic nerve, Biology, Intermountain, Football, Environment

The Miller Family Campus’ Infusion Center opened for one day before the grand opening to give them the treatments they needed, closer to home.

Key Points: 
  • The Miller Family Campus’ Infusion Center opened for one day before the grand opening to give them the treatments they needed, closer to home.
  • Everyone at the new campus has been so amazing to work with!”
    The new Miller Family Campus is a full-service children’s hospital providing nearly all the same specialty pediatric services that patients receive at the Salt Lake Campus.
  • The Miller Family Campus is part of Intermountain Health’s Primary Promise to build the nation’s model health system for children.
  • For more information about the new Miller Family Campus in Lehi, visit primarychildrens.org/lehi .

Pursuant Health Unveils FDA-Cleared Retinal Imaging Kiosk - a First in On-Demand Healthcare

Retrieved on: 
Friday, January 12, 2024
Diabetes, Research, Pulse, Health, Hypertension, Paratriathlon, Optic nerve, Public, Diabetic retinopathy, CDC, FDA, Common, BMI, Body mass index, Blood, Ageing, Blood pressure, Medical imaging

ATLANTA, Jan. 12, 2024 /PRNewswire/ -- Pursuant Health announced today a breakthrough in making a critical preventive care service more accessible to the American public. Pursuant Health's newest kiosk model, now equipped with state-of-the-art retinal imaging technology, has received 510(k) clearance from the U.S. Federal Drug Administration (FDA). This kiosk is the first to offer self-service retinal imaging, enabling individuals to capture their own images quickly and effortlessly.

Key Points: 
  • Pursuant Health's newest kiosk model, now equipped with state-of-the-art retinal imaging technology, has received 510(k) clearance from the U.S. Federal Drug Administration (FDA).
  • This kiosk is the first to offer self-service retinal imaging, enabling individuals to capture their own images quickly and effortlessly.
  • Leslie Sommers, CEO of Pursuant Health, emphasizes the kiosk's role in simplifying healthcare: "Our goal is to streamline healthcare for everyone involved.
  • Looking ahead, Pursuant Health aspires to leverage retinal imaging for broader health analysis.

Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Retrieved on: 
Saturday, January 6, 2024
Urinary tract infection, Patient, Medical Subject Headings, Marketing, Agency, Jaw, INN, Interferon beta-1a, Immune system, Fever, Tears, ATC, Disability, Multiple sclerosis, Kidney, Hypertension, International, Blood, RRMS, Attack, Spinal cord, Disease, Headache, Language, Brain, Myocardial infarction, Eye, Heart, Inflammation, Thyroid, Stroke, Head, Angina, European Medicines Agency, Infection, Coagulopathy, Lymphocyte, HIV, Select, Central nervous system, Human, Safety, Anatomy, Checklist, Sclerosis, IIA, Optic nerve, Neck, Rash, CD52, Medical device

Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Urine, Medical Subject Headings, Diarrhea, Marketing, INN, Risk, Immune system, Stomach, Multiple sclerosis, ATC, Pain, Capsule, International, Spinal cord, Disease, PML, Nausea, Language, Brain, Mouth, Eye, Inflammation, Flushing, Antioxidant, European Medicines Agency, Gene, Glatiramer acetate, Select, Central nervous system, Patient, Cell, Safety, Encephalitis, Anatomy, IIA, Optic nerve, Skin, Medical device

Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Urine, Medical Subject Headings, Diarrhea, Marketing, INN, Risk, Immune system, Stomach, Interferon beta-1a, ATC, Pain, Multiple sclerosis, Capsule, International, RRMS, Spinal cord, Disease, PML, Ageing, Nausea, Language, Brain, Mouth, Eye, Inflammation, Flushing, European Medicines Agency, Food, Gene, Glatiramer acetate, Select, Central nervous system, Patient, Safety, Encephalitis, Anatomy, Sclerosis, Optic nerve, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised